

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## **Prenatal cannabis exposure and childhood outcomes: Results from the ABCD study**

Sarah E. Paul,<sup>1</sup> Alexander Hatoum,<sup>2</sup> Jeremy D. Fine,<sup>1</sup> Emma C. Johnson,<sup>2</sup> Isabella Hansen,<sup>1</sup>  
Nicole R. Karcher,<sup>1</sup> Allison L. Moreau,<sup>1</sup> Erin Bondy,<sup>1</sup> Yueyue Qu,<sup>1</sup> Ebony B. Carter,<sup>3</sup> Cynthia E  
Rogers,<sup>2</sup> Arpana Agrawal,<sup>2</sup> Deanna M. Barch,<sup>1,2</sup> Ryan Bogdan<sup>1</sup>

<sup>1</sup> Department of Psychological and Brain Sciences, Washington University, St. Louis, MO

<sup>2</sup> Department of Psychiatry, Washington University School of Medicine, St. Louis, MO

<sup>3</sup> Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO

Author's note: Correspondence concerning this article should be addressed to Ryan Bogdan (email: rbogdan@wustl.edu, address: CB 1125 Psychological and Brain Sciences Bldg Room 453, Washington University in St. Louis, One Brookings Drive, St. Louis, MO 63130, USA) and Sarah Paul (email: spaul24@wustl.edu, address: CB 1125 Psychological and Brain Sciences Bldg Room 453, Washington University in St. Louis, One Brookings Drive, St. Louis, MO 63130, USA)

37 **ABSTRACT**

38 **Importance:** In light of increasing cannabis use among pregnant women, the Surgeon General of  
39 the United States issued an advisory against the use of marijuana during pregnancy on August  
40 29<sup>th</sup>, 2019.

41 **Objective:** To determine whether cannabis use during pregnancy is associated with adverse  
42 outcomes among offspring.

43 **Design:** Cross-sectional analysis of the baseline session of the ongoing longitudinal Adolescent  
44 Brain and Cognitive Development (ABCD) study.

45 **Setting:** Data were collected from 22 sites across the United States between 2016 and 2018.

46 **Participants:** Children ages 9-11 (n=11,489) and their parent or caregiver.

47 **Exposure:** Prenatal marijuana exposure prior to and following maternal knowledge of  
48 pregnancy.

49 **Main Outcomes and Measures:** Child psychopathology symptomatology (i.e., psychotic-like  
50 experiences and internalizing, externalizing, attention, thought, and social problems), cognition,  
51 sleep, birth weight, gestational age at birth, body mass index (BMI), and brain structure (i.e.,  
52 total intracranial volume, white matter volume, gray matter volume). Covariates included  
53 familial (e.g., income, familial psychopathology), pregnancy (e.g., prenatal vitamin use, whether  
54 the pregnancy was planned), and child (e.g., birth weight, substance use) variables.

55 **Results:** Among 11,489 children (age 9.9±0.6 years; 47.78% female), 655 (5.70%) were  
56 prenatally exposed to cannabis in total. Marijuana use prior to (n=648; 5.64%) and following  
57 (n=242; 2.11%) maternal knowledge of pregnancy were associated with increased offspring  
58 psychopathology characteristics (i.e., psychotic-like experiences and internalizing, externalizing,  
59 attention, thought, social, and sleep problems) and BMI as well as reduced cognition, birth

60 weight, and brain structure (i.e., total white and gray mater volumes; all  $ps_{fidr} < .007$ ), but not  
61 gestational age at birth. Exposure following maternal knowledge of pregnancy remained  
62 significantly associated with psychopathology, cognition, and birth weight outcomes when  
63 including potentially confounding variables (all  $ps < 0.046$ ). All associations with exposure prior  
64 to maternal knowledge of pregnancy were nonsignificant when considering potentially  
65 confounding variables (all  $ps > 0.06$ ).

66 **Conclusions and Relevance:** Prenatal cannabis exposure, and its correlated factors, may  
67 increase risk for psychopathology and reduced cognition during middle childhood as well as  
68 reduced birthweight. Consistent with recent recommendations by the Surgeon General,  
69 marijuana use during pregnancy should be discouraged.

70

71

72 **INTRODUCTION**

73 Alongside increasingly permissive sociocultural attitudes and laws surrounding cannabis,<sup>1</sup> past  
74 month use among pregnant women increased by 106% from 2002(3.4%) to 2017(7.0%) in the  
75 United States.<sup>2</sup> Tetrahydrocannabinol (THC), the psychoactive component of cannabis, crosses  
76 the placenta<sup>3</sup> and interfaces with the endocannabinoid system, which critically influences neural  
77 development.<sup>3-5</sup> Thus, it is plausible that cannabis use during pregnancy may impact offspring.  
78 Indeed, the alarming increase of cannabis use among pregnant mothers,<sup>2,6-8</sup> and evidence linking  
79 prenatal exposure to adverse outcomes in children<sup>9-13</sup> prompted the Surgeon General of the  
80 United States to release an advisory against cannabis use during pregnancy and breastfeeding on  
81 August 29<sup>th</sup> 2019.<sup>14</sup>

82 Despite the increasing prevalence of prenatal cannabis exposure, there have been  
83 relatively few investigations of its association with child outcomes. These studies have found  
84 evidence linking prenatal marijuana exposure to reduced birth weight<sup>15</sup> and cognition<sup>16,17</sup> as well  
85 as heightened risk for premature birth,<sup>18</sup> psychopathology (i.e., psychosis, internalizing,  
86 externalizing)<sup>19-21</sup> and sleep problems<sup>22</sup> among children. However, there has been limited cross-  
87 study replication,<sup>e.g.,23-25</sup> and studies have typically been unable to account for other potential  
88 confounding factors (e.g., maternal education, prenatal vitamin usage, child substance use,  
89 familial risk), leaving it possible that associations between prenatal marijuana exposure and  
90 negative outcomes among children may not be independent of them. Indeed, the National  
91 Academies of Sciences, Engineering, and Medicine recently concluded that only reduced birth  
92 weight has been robustly linked to prenatal cannabis exposure.<sup>13</sup>

93 Using data from the Adolescent Brain Cognitive Development (ABCD) study (data  
94 release 2.0.1) of 11,875 children, we test whether prenatal marijuana exposure before and after

95 maternal knowledge of pregnancy is associated with psychopathology (i.e., internalizing,  
96 externalizing, attention, thought and social problems, psychotic-like experiences), sleep,  
97 cognition, birth weight, premature birth, body mass index (BMI), and gross brain structure (i.e.,  
98 white and gray matter volumes as well as intracranial volume). This represents a comprehensive  
99 extension of our prior investigation of prenatal cannabis exposure and psychotic-like experiences  
100 among the initial ABCD data release (n=4,361).<sup>26</sup> We hypothesized that prenatal marijuana  
101 exposure before and after maternal knowledge of pregnancy would be associated with greater  
102 risk for psychopathology, premature birth, and sleep problems, as well as reduced cognition,  
103 birth weight, BMI, and brain structure metrics when not considering potentially confounding  
104 variables. However, given that endocannabinoid receptors are not expressed in the fetus until 5-6  
105 weeks<sup>9,27,28</sup> which roughly corresponds to when, in this study, mothers learned that they were  
106 pregnant ( $6.91 \pm 6.75$  weeks), we hypothesized that these associations would only be robust to  
107 the inclusion of potentially confounding covariates when marijuana use occurred following  
108 maternal knowledge of pregnancy.

109

110

111

112 **METHODS**

113 **Participants**

114 Data came from children ( $n=11,875$ ;  $M_{age} = 9.9\pm 0.6$  years; 47.85% girls; 74.13% White), born  
115 between 2005 and 2009 to 9,987 mothers through 10,801 pregnancies, who completed the  
116 baseline session of the ongoing longitudinal Adolescent Brain Cognitive Development (ABCD)  
117 study (data release 2.0.1; <https://abcdstudy.org/>).<sup>29</sup> The study includes a family-based design in  
118 which twin ( $n=2,108$ ), triplet ( $n=30$ ), non-twin siblings ( $n=1,589$ ), and singletons ( $n=8,148$ ) were  
119 recruited. All parents/caregivers (85.3% biological mothers)<sup>a</sup> and children provided written  
120 informed consent and verbal assent, respectively, to a research protocol approved by the  
121 institutional review board at each data collection site ( $n=22$ )<sup>b</sup> throughout the United States  
122 (<https://abcdstudy.org/sites/abcd-sites.html>). For our analyses, only data from participants with  
123 non-missing data on prenatal cannabis exposure were included ( $n=11,489$  [87.6% of  
124 parent/caregivers were biological mothers];  $M_{age} = 9.9\pm 0.6$  years; 47.78% girls; 74.76% self-  
125 reported White; 2,072 twins, 30 triplets, 1,523 non-twin siblings, 7,864 singletons; **Table 1**).

126

127 **Measures**

128 All measures are described in the **Supplement** and **Table 1**.

129 **Prenatal Cannabis Exposure.** Child prenatal marijuana exposure before ( $n=648$ ) or after  
130 ( $n=242$ ) maternal knowledge of pregnancy were coded as separate dichotomous variables based  
131 upon parent/caregiver<sup>a</sup> retrospective report.

---

<sup>a</sup> All analyses were rerun excluding parent/caregiver respondents who were not the mother; all results and conclusions remain the same; **Supplement**).

<sup>b</sup> Cornell University was an original collection site that collected data from 34 participants, before being moved to Yale University. ABCD documentation reports 21 data collection sites and does not list Cornell; our analyses nested data based on 22 data collection sites, including the original Cornell site.

132 **Psychotic-like experiences.** The total score of the *Prodromal Questionnaire-Brief Child Version*  
133 (PQ-BC)<sup>30,31</sup> was used to assess child-reported psychotic-like experiences (PLEs). Higher scores  
134 indicate more PLEs.

135

136 **Internalizing, Externalizing, Attention, Thought, and Social Problems.** The *Child Behavior*  
137 *Checklist* (CBCL)<sup>32</sup> was used to assess broad spectrum internalizing (INT) and externalizing  
138 (EXT) as well as attention (ATN), thought (THT), and social (SOC) problems in children  
139 according to parent/caregiver report. Higher scores are reflective of more problems.

140

141 **Sleep Problems.** The total score of the *Sleep Disturbance Scale for Children* (SDSC)<sup>33</sup> was used  
142 to assess parent/caregiver-reported sleep problems in children. Higher scores reflect more sleep  
143 problems.

144

145 **Cognition.** The *National Institutes of Health Toolbox Cognition Battery–Total Cognition*  
146 *Composite*<sup>34</sup> indexed child cognitive ability. Higher scores are reflective of greater cognitive  
147 performance.

148

149 **Gestational Age at Birth, Birth Weight and Body Mass Index.** A parent/caregiver  
150 retrospectively reported their child's gestational age at birth in weeks and birth weight. BMI was  
151 calculated using measured height and weight at the baseline assessment.

152

153 **Brain Structure: Total Intracranial, White Matter, and Gray Matter Volumes.** Freesurfer  
154 v5.3 was used to estimate total intracranial volume (ICV), gray matter volume (GMV), and white  
155 matter volume (WMV).

156

157 **Covariates.** The following variables were dummy coded: *race/ethnicity, family history of*  
158 *psychopathology, prenatal exposure to tobacco or alcohol before or after maternal knowledge of*  
159 *pregnancy, unplanned pregnancy, prenatal vitamin usage, child alcohol try, child tobacco try,*  
160 *child self-reported gender, and twin/triplet status.* Annual household income was treated as a 5-  
161 level categorical variable. The following continuous covariates were included: *birthweight,*  
162 *maternal age at birth, gestational age when pregnancy was discovered (weeks), child age, and*  
163 *maternal education (years).* Total intracranial volume was further included as a covariate only in  
164 models with gray and white matter volumes as outcomes. Polygenic scores (PGS) for  
165 schizophrenia, educational attainment, birthweight, and cannabis use as well as ancestrally-  
166 informative principal components (n=10) were included as covariates in *post-hoc* analyses within  
167 the genomically-confirmed European ancestry subsample (**Statistical Analyses; Supplement**).

168 Non-prevalent substance use among children (n=80) or by women while they were  
169 pregnant (n=185) as well as extreme premature birth (n=148), and non-biological mother  
170 parent/caregiver report (n=1,427) were not included as covariates; we conducted *post hoc*  
171 analyses excluding individuals on these variables (**Supplement**).

172

### 173 **Statistical Analyses**

174 Continuous predictor and outcome variables were winsorized to minimize the influence of  
175 extreme values (i.e., any values  $\pm 3$  SDs were set at the  $\pm 3$  SD point). We used linear mixed-



176 effects models with random intercept parameters to account for non-independence of site and  
177 family membership for all non-imaging analyses and scanner and family for all imaging  
178 analyses, with the lme4 package in Rv3.6.0.<sup>35</sup>

179 We examined the association between prenatal cannabis exposure before and after  
180 maternal knowledge of pregnancy (each coded 0/1 separately) and outcomes using three analytic  
181 approaches. *First*, we tested whether prenatal marijuana exposure prior to and after maternal  
182 knowledge were associated with outcomes of interest in independent nested mixed models with  
183 no fixed effect covariates. We adjusted for multiple testing using Benjamini Hochberg false  
184 discovery rate correction ( $fdr_{BH}$ ). *Second*, for any associations that were significant after multiple  
185 testing correction, we examined whether they were robust to the inclusion of potentially  
186 confounding covariates; here, we simultaneously entered prenatal marijuana use before and after  
187 maternal knowledge of pregnancy alongside the covariates described above (except genomic  
188 data). To address concerns of overfitting, we reran all analyses including only covariates that  
189 were significantly associated with the outcome (**Supplement**). We conducted *post hoc* analyses  
190 to examine subcomponents of significant associations (i.e., CBCL INT and EXT subscales,  
191 cognition subcomponents; **Supplement**). *Third* and finally, to account for the possible  
192 confounding effects of genomic liability to offspring outcomes not accounted for by familial  
193 history, we examined whether associations remained significant when accounting for polygenic  
194 scores (PGS) derived using summary statistics from genome-wide association studies (GWASs)  
195 of related outcomes (**Supplement**).<sup>36</sup> Here, we evaluated whether any associations robust to  
196 covariate inclusion were present in the subsample of individuals with genomically-confirmed  
197 European ancestry (n=4,644) to ensure that any differences could not be attributable to power  
198 reductions, before examining whether these associations were robust to the inclusion of GWAS-

199 weighted PGS (i.e., schizophrenia,<sup>37</sup> educational attainment,<sup>38</sup> cannabis use,<sup>39</sup> polygenic scores

200 for PLEs; cannabis use for social problems; birth weight<sup>40</sup> and cannabis use for birth weight;

201 **Supplement).**

202

203

204 **RESULTS**

205 Among 11,489 children (mean [SD]: age, 9.9 [0.6] years; 5,488 [47.78%] girls), 655 (5.85%) were  
206 prenatally exposed to marijuana (**Table 1**). Of these, 413 were exposed only before maternal  
207 knowledge of pregnancy while 235 were exposed both before and after maternal knowledge, and 7  
208 only after maternal knowledge. Mothers learned of their pregnancy at  $6.91 \pm 6.75$  weeks. Rates of  
209 tobacco and alcohol use during pregnancy, prior to and following maternal knowledge of  
210 pregnancy, were higher than cannabis use (**Table 1**) and modestly correlated with prenatal  
211 marijuana exposure ( $r_s$  0.11-0.34; **Supplemental eTable 1**).

212

213 **Prenatal Cannabis Exposure After Maternal Knowledge of Pregnancy**

214 Prenatal marijuana exposure *after* maternal knowledge of pregnancy was significantly associated  
215 with higher PLEs, BMI and internalizing, externalizing, attention, thought, social, and sleep  
216 problems, as well as lower cognition, birth weight, and intracranial and gray and white matter  
217 volumes (all  $|B_s| > 0.27$ , all  $p_{s_{fdr}} < 0.002$ ; **Table 2**), but not gestational age at birth ( $B = 0.14$ ,  
218  $p_{fdr} = 0.271$ ). PLEs, birth weight, and cognition, as well as internalizing, externalizing, attention,  
219 thought, and social problems, remained significantly associated even after accounting for  
220 potentially confounding covariates (all  $|B_s| > 0.52$ , all  $p_s < 0.046$ ), but sleep problems, BMI, and total  
221 intracranial, gray matter, and white matter volumes were not (all  $|B_s| < 0.87$ ,  $p_s > 0.27$ ; **Figure 1**;  
222 **Table 3**; **Supplemental eTables 2-8**). *Post hoc* analyses showed globally similar associations  
223 across subfacets of EXT, but not INT or cognition (**Supplemental eTable 9**).

224 Stepwise analyses of confounding covariates revealed that reductions in significance could  
225 not generally be attributed to a small collection of variables (**Supplement**). *Post Hoc Analyses*  
226 excluding: children who engaged in non-prevalent substance use, were exposed to other illicit

227 substances prenatally, were born at extreme levels of prematurity, or whose biological mothers were  
228 not the parent/caregiver respondent revealed similar associations and consistent conclusions  
229 (**Supplemental eTable 10-13**). Finally, in the subsample of children with genomically-confirmed  
230 European ancestry (N=4,644; 3.94% reporting any prenatal exposure), PLEs, social problems, and  
231 birth weight remained significantly associated with prenatal exposure to cannabis after maternal  
232 knowledge of pregnancy even after accounting for covariates (all  $|Bs|>0.97$ , all  $ps<0.016$ ;  
233 **Supplemental eTable 14**) and when further accounting for child PGS for schizophrenia,  
234 educational attainment, birth weight, and/or cannabis use ( $|Bs|>0.95$ , all  $ps<0.018$ ; **Supplemental**  
235 **eTables 15-18**).

236

### 237 **Prenatal Cannabis Exposure Prior to Maternal Knowledge of Pregnancy**

238 Prenatal marijuana exposure *prior to* maternal knowledge of pregnancy was significantly associated  
239 with all outcomes (all  $|Bs|>0.15$ , all  $ps_{fdr}<7.0*10^{-3}$ ) except gestational age at birth ( $B=0.076$ ,  
240  $p_{fdr}=0.334$ ; **Table 2**). No associations remained significant after accounting for potentially  
241 confounding covariates, but a nominal trend for increased (directionally opposite to results without  
242 covariates) cognition emerged (**Table 3; Supplemental eTables 2-8**). Stepwise analysis of  
243 confounding covariates revealed that no small group of covariates was responsible for attenuating  
244 these associations (but see Attention and Thought problems; **Supplemental eResults**).

245

246

247

248 **DISCUSSION**

249 Prenatal cannabis exposure following maternal knowledge of pregnancy is associated with  
250 elevated psychopathology risk and reduced cognition during middle childhood as well as reduced  
251 birth weight (**Tables 2-3**). That these associations were robust to the inclusion of potentially  
252 confounding variables increases the plausibility that prenatal cannabis exposure may  
253 independently contribute to the development of behavioral problems in children. In contrast to  
254 increasingly permissive attitudes surrounding marijuana use among pregnant mothers,<sup>41</sup> and  
255 recommendations by dispensaries to use marijuana to combat pregnancy-related nausea,<sup>42</sup> these  
256 findings align with recent recommendations by the Surgeon General<sup>14</sup> and raise concern  
257 surrounding the potential impact of in utero exposure to marijuana on mental health and  
258 cognitive outcomes in children.

259 All studied outcomes, except gestational age at birth, were associated with prenatal  
260 exposure before and after maternal knowledge of pregnancy (**Table 2**); however, only  
261 associations between prenatal exposure post-maternal knowledge of pregnancy and child  
262 psychopathology, cognition, and birth weight were robust to covariate inclusion (**Table 3**). There  
263 are several potential non-mutually exclusive explanations for these findings. *First*,  
264 endocannabinoid system ontogeny and signaling may play a role. Endocannabinoid type 1  
265 receptors (CB<sub>1</sub>Rs), which non-human animal data suggest are critical for THC's impact on the  
266 developing brain,<sup>43</sup> are not known to be expressed before the equivalent of 5 to 6 weeks gestation  
267 in humans.<sup>9</sup> As such, independent effects of cannabis on behavioral outcomes in children may  
268 only arise when sufficient CB<sub>1</sub>Rs are present in the fetus, which may not occur until after many  
269 women learn they are pregnant (**Table 3**).<sup>c</sup> *Second*, use despite knowledge of pregnancy might

---

<sup>c</sup> It is possible that exposure before this time might not directly impact fetal brain development, though it remains possible for indirect effects to arise indirectly through endocannabinoid receptor expression in the placenta.<sup>44</sup>

270 represent a more severe form of cannabis use, indicative of higher and more frequent prenatal  
271 and potential post-natal exposure (e.g., during breastfeeding) consistent with a dose-response  
272 relationship that may reflect variability in liability and/or potential causal influence.<sup>45</sup> *Third*,  
273 sustained use during pregnancy may reflect a genetic predisposition to the observed negative  
274 outcomes, and the resulting associations may simply reflect pleiotropy.<sup>46,47</sup> However, controlling  
275 for maternal behavior and genetic susceptibility did not eliminate associations (**Supplemental**  
276 **eTables 2-3, 15**). *Fourth*, associations may be attributable to an unmeasured common variable  
277 (e.g., paternal germline exposure to cannabis)<sup>48</sup> or an alternate derivation of an included  
278 confounder.<sup>d</sup>

279 Self-administration of cannabis, especially when heavy and early, has been strongly  
280 associated with increased psychopathology, particularly psychosis.<sup>49</sup> In contrast to acute THC  
281 psychotomimetic effects,<sup>50</sup> mounting evidence supports common genetic liability as a major  
282 contributor to this relationship,<sup>39,47,51-53</sup> though evidence also supports potential causal effects of  
283 psychosis liability on cannabis use,<sup>39,47</sup> and vice versa.<sup>54,55</sup> Consistent with prior work,<sup>21</sup> we find  
284 that child psychosis liability (i.e., PLEs and thought problems) is increased among children  
285 prenatally exposed to cannabis. Critically building upon this literature, this relationship was only  
286 robust to potential confounds when exposure occurred following maternal knowledge of  
287 pregnancy. That the relationship with PLEs remained after accounting for family history of  
288 psychosis as well as child polygenic risk for schizophrenia, educational attainment, and cannabis  
289 use, raises the intriguing possibility that associations between prenatal exposure and psychosis  
290 risk may not be entirely attributable to common SNP genomic liability, at least as indexed by

---

<sup>d</sup> Notably, accounting for scores from a 4-item assessment of psychotic-like experiences in mothers (**Supplement**) as opposed to familial history of psychosis, which has a low endorsement rate, does not alter the significance of the association between prenatal marijuana exposure and PLEs in offspring (**Supplemental eTable 18**)

291 polygenic scores derived from the largest current GWASs that approximate the child outcomes  
292 under study (but see also **Limitations** below). Indeed, putative mechanisms underlying the  
293 elevated likelihood of psychosis in children prenatally exposed to cannabis may be distinct from  
294 those associated with self-administered cannabis use. For instance, while the endocannabinoid  
295 system primarily functions as an on-demand retrograde neuromodulatory system through CB<sub>1</sub>R  
296 signaling throughout life, CB<sub>1</sub>Rs during the prenatal period are ubiquitously expressed in neural  
297 progenitors and contribute to neural migration, axonal elongation, and synaptic formation.<sup>9</sup>  
298 Although such proposed mechanisms would be consistent with neurodevelopmental theories of  
299 psychosis,<sup>56</sup> the associations we observed with gross brain morphology metrics were not robust  
300 to covariate inclusion. It remains possible that neurodevelopmental differences (e.g., synaptic  
301 formation) may not be detectable using MRI, may be regionally specific, or may not emerge  
302 until later developmental stages.

303         In addition to replicating the well validated association with reduced birth weight,<sup>13</sup>  
304 children prenatally exposed to cannabis following maternal knowledge of pregnancy had  
305 elevated internalizing, externalizing, attention, and social problems, as well as reduced cognition.  
306 As has been shown for the increased likelihood of tobacco smoking during pregnancy in women  
307 with ADHD and the confounding of consequent associations with offspring ADHD,<sup>57-59</sup> women  
308 with externalizing features (which include cognitive differences) might be more likely to  
309 continue using cannabis during their pregnancy. Genetically informed designs (e.g., sibling  
310 crossover design where non-twin siblings are discordant for prenatal exposure)<sup>60,61</sup> provide one  
311 mechanism for identifying such familial sources of confounding.<sup>62,63</sup> Notably, prenatal exposure  
312 to alcohol and tobacco were also related to offspring psychopathology and cognition, but these  
313 associations were predominantly with exposure prior to, as opposed to following, maternal

314 knowledge of pregnancy and observed inconsistently relative to associations with cannabis  
315 exposure (**Supplemental eTables 2-3**). The lack of association with alcohol or tobacco use  
316 subsequent to knowledge of pregnancy may indicate the more pronounced public awareness of  
317 fetal risks and obstetric oversight of the use of these substances that leads to greater reductions in  
318 use post-knowledge of pregnancy, relative to cannabis.<sup>8,64</sup> Alternatively, prenatal cannabis  
319 exposure may serve as a proxy for exposure to a permissive home environment that promotes  
320 externalizing behaviors and related cognitive disengagement.<sup>65</sup> In addition, factors broadly  
321 correlated with prenatal substance use, such as restricted access to health care, birth-related  
322 complications and postpartum maternal behaviors, may plausibly contribute to these  
323 associations.<sup>66</sup>

324         Some limitations are noteworthy. First, parent/caregivers may have underreported  
325 marijuana use during pregnancy; however, our estimates are consistent with other national  
326 datasets, including toxicology based prevalence estimates.<sup>67</sup> Second, although the ABCD study  
327 represents the largest integrative study of child health and substance use and is among the largest  
328 studies of prenatal exposure and child outcomes, there were a relatively small number of  
329 participants who were exposed to cannabis prenatally which reduces power. Third, marijuana  
330 concentration differs significantly between fetuses whose mothers use cannabis once per month  
331 compared to once per day.<sup>15</sup> There are limited or no data on potency, frequency, timing and  
332 quantity of cannabis exposure during pregnancy in this dataset; further, the limited number of  
333 prenatally exposed individuals limits the utility of more refined analyses of cannabis use  
334 variability in this dataset.<sup>68</sup> Fourth, while we were able to account for many known familial,  
335 pregnancy, and child related confounding variables, the role of unmeasured confounders cannot  
336 be discounted. Relatedly, while we account for underlying genetic vulnerability using both



337 familial history as well as polygenic scores, it is possible that the current GWASs from which  
338 PGS weighting was determined are underpowered and/or not generalizable across development  
339 and as such do not adequately represent genomic risk for the specific child outcomes under  
340 study, consistent with the lack of association between schizophrenia PGS and PLEs and thought  
341 problems (**Supplemental eTable 16-17**).

342

### 343 **Conclusions**

344 Despite increasingly permissive social attitudes and the marked relaxation of legal restrictions on  
345 cannabis use,<sup>1</sup> prenatal cannabis exposure, and the correlated risks that it indexes, may place  
346 offspring at increased risk for psychopathology and reduced cognition in middle childhood. In  
347 the context of increasing marijuana use among pregnant women,<sup>2,6</sup> it is clear that more studies on  
348 the relationship between prenatal cannabis exposure and offspring developmental outcomes are  
349 needed to examine potential causal effects, moderating or protective factors, and biological  
350 mechanisms at play.<sup>69,70</sup> Similar to the highly effective messaging surrounding the adverse  
351 consequences of alcohol and tobacco exposure during pregnancy, education regarding the  
352 potential harms associated with prenatal marijuana use is necessary. Currently, cannabis use  
353 during pregnancy should be discouraged by care providers and dispensaries.<sup>11,14</sup>

354

355

356

357

358

359 **ACKNOWLEDGEMENTS**

360

361 Data for this study were provided by the Adolescent Brain Cognitive Development (ABCD)  
362 study which was funded by awards U01DA041022, U01DA041025, U01DA041028,  
363 U01DA041048, U01DA041089, U01DA041093, U01DA041106, U01DA041117,  
364 U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174,  
365 U24DA041123, and U24DA041147 from the NIH and additional federal partners  
366 (<https://abcdstudy.org/federal-partners.html>). Authors received funding support from NIH: Dr.  
367 Hatoum (T32-DA007261), Dr. Johnson (F32 AA027435), Dr. Karcher (MH014677), Dr. Carter  
368 (R01-DA046224), Dr. Rogers (R01-DA046224), Dr. Agrawal (5K02DA32573; R01-  
369 DA046224), Dr. Barch (R01-MH113883; R01-MH066031; U01-MH109589; U01-A005020803;  
370 R01-MH090786), Dr. Bogdan (R01-AG045231, R01-HD083614, R01-AG052564, R21-  
371 AA027827, R01-DA046224). RB, SEP, JF, and ALM developed the research questions. SEP,  
372 JDF, AH, EJ, RB conducted analyses. SEP and RB drafted the manuscript. AH, IH, JDF, EJ,  
373 ALM, EB, YQ, NRK, EBC, CER, AA, DMB provided critical revision of the manuscript for  
374 important intellectual content. SEP, AH, JDF, EJ, and RB had full access to all data and take  
375 responsibility for the integrity of the data and accuracy of analyses. Conflict of interest  
376 disclosures: No disclosures were reported. Data on birth weight for polygenic risk scores has  
377 been contributed by the EGG Consortium using the UK Biobank Resource and has been  
378 downloaded from [www.egg-consortium.org](http://www.egg-consortium.org). We would like to acknowledge all participating  
379 groups of the International Cannabis Consortium, and in particular the members of the working  
380 group including S. Stringer, C. Minica, K. Verweij, H. Mbarek, E. Derks, N. Gillespie, and J.  
381 Vink.

382 **Table 1. ABCD Sample Characteristics.**

Variable (N)	Prenatal Cannabis Exposure Post-Knowledge of Pregnancy (N=242)	No Prenatal Cannabis Exposure Post-Knowledge of Pregnancy			Total (N=11247)	Total (11489)
		Prenatal Cannabis Use Before Knowing (N=413)	No Prenatal Use (N=10834)	Total (N=11247)		
<b>Child Variables</b>						
Age in years (11,489)	9.83 ± 0.62	9.89 ± 0.63	9.92 ± 0.62	9.91 ± 0.62	9.91 ± 0.62	
Gender, female (11,486)	131 (54.13%)	194 (46.97%)	5164 (47.66%)	5358 (47.64%)	5489 (47.78%)	
Birthweight in oz. (11,113)	108.80 ± 23.84	112.6 ± 22.57	112.30 ± 23.45	112.30 ± 23.42	112.20 ± 23.43	
<i>Race/Ethnicity (11,489)<sup>a</sup></i>						
White	144 (59.50%)	242 (58.60%)	8203 (75.72%)	8445 (75.09%)	8589 (74.76%)	
Black	110 (45.45%)	172 (41.65%)	2094 (19.33%)	2266 (20.15%)	2376 (20.68%)	
Asian	5 (2.07%)	13 (3.15%)	692 (6.39%)	705 (6.27%)	710 (6.18%)	
Pacific Islander	1 (0.41%)	5 (1.21%)	63 (0.58%)	68 (0.60%)	69 (0.60%)	
Native American	14 (5.79%)	17 (4.12%)	3.13 (3.17%)	360 (3.20%)	374 (3.26%)	
Hispanic	34 (14.05%)	89 (21.55%)	2215 (20.44%)	2304 (20.49%)	2338 (20.35%)	
Other	8 (3.31%)	34 (8.23%)	722 (6.66%)	756 (6.72%)	764 (6.65%)	
<i>Child Lifetime Substance Exposure</i>						
Alcohol Try (11,482)	52 (21.49%)	113 (27.36%)	2417 (22.31%)	2530 (22.49%)	2582 (22.49%)	
Tobacco Try (11,482)	10 (4.13%)	12 (2.91%)	98 (0.90%)	110 (0.98%)	120 (1.05%)	
Marijuana Try (11,482)	3 (1.24%)	2 (0.48%)	9 (0.08%)	11 (0.10%)	14 (0.12%)	
<b>Pregnancy and Family Variables</b>						
Unplanned Pregnancy (11,377)	170 (70.25%)	111 (26.88%)	3865 (35.67%)	4166 (37.04%)	4336 (37.74%)	
Maternal Age at Birth (11,336)	25.33 ± 6.36	25.39 ± 5.90	29.71 ± 6.14	29.55 ± 6.18	29.47 ± 6.22	
Prenatal Vitamin Use (11,236)	178 (73.55%)	392 (94.92%)	10172 (93.89%)	10564 (93.93%)	10742 (93.50%)	
Week Learned Pregnancy (10,375)	8.30 ± 7.39	7.84 ± 6.48	6.85 ± 6.74	6.88 ± 6.74	6.91 ± 6.75	
Maternal Education: Years (10974)	13.68 ± 2.01	14.27 ± 2.23	15.27 ± 2.62	15.24 ± 2.61	15.21 ± 2.61	
<i>Household Inc (10,507)</i>						
\$0-\$49,999k	136 (56.20%)	204 (49.39%)	2764 (25.51%)	2968 (26.39%)	3104 (27.02%)	
\$50k-\$74,999k	32 (13.22%)	54 (13.08%)	1368 (12.63%)	1422 (12.64%)	1454 (12.67%)	
\$75k-\$99,999k	29 (11.98%)	37 (8.96%)	1445 (13.34%)	1482 (13.18%)	1511 (13.15%)	
\$100k-\$199,999k	21 (8.68%)	60 (14.53%)	3136 (28.95%)	3196 (28.42%)	3217 (28.00%)	
\$200k or more	2 (0.83%)	21 (5.08%)	1198 (11.06%)	1219 (10.84%)	1221 (10.63%)	
<i>Family History of Psychopathology<sup>b</sup></i>						
Psychosis (11,205)	15 (6.20%)	23 (5.57%)	223 (2.06%)	246 (2.19%)	261 (2.27%)	
Depression (11,329)	139 (57.44%)	194 (46.97%)	3280 (30.28%)	3474 (30.89%)	3613 (31.45%)	
Anxiety (11,150)	58 (23.97%)	101 (24.46%)	1216 (11.22%)	1317 (11.71%)	1375 (11.97%)	
Antisocial Behavior (11,320)	123 (50.83%)	151 (36.56%)	1146 (10.58%)	1298 (11.54%)	1421 (12.37%)	
Mania (11,138)	47 (19.42%)	46 (11.14%)	493 (4.55%)	539 (4.79%)	586 (5.10%)	
<i>Prenatal Substance Exposure Before Knowing of Pregnancy</i>						
Alcohol (11,072)	135 (55.79%)	255 (61.74%)	2391 (22.07%)	2646 (23.53%)	2781 (24.21%)	
Tobacco (11,430)	59 (65.70%)	230 (55.69%)	1117 (10.31%)	1347 (11.98%)	1506 (13.11%)	
Cannabis (11,489)	235 (97.11%)	413 (100.00%)	0 (0.00%)	413 (3.67%)	648 (5.64%)	
<i>Prenatal Substance Exposure After Knowing of Pregnancy</i>						
Alcohol (11,446)	63 (26.03%)	13 (3.15%)	214 (1.98%)	227 (2.02%)	290 (2.52%)	
Tobacco (11,458)	114 (47.11%)	60 (14.53%)	392 (3.62%)	452 (4.02%)	566 (4.93%)	
Cannabis (11,489)	242 (100.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	242 (2.11%)	
<b>Child Primary Outcomes of Interest</b>						
Psychotic-like Experiences (11,477)	3.58 ± 3.98	3.17 ± 3.67	2.57 ± 3.52	2.59 ± 3.53	2.61 ± 3.54	
Internalizing Sx (CBCL) (11,483)	7.83 ± 7.39	6.41 ± 6.08	4.88 ± 5.38	4.94 ± 5.41	5.00 ± 5.48	
Externalizing Sx (CBCL) (11,483)	10.06 ± 9.15	6.44 ± 7.36	4.13 ± 5.47	4.22 ± 5.56	4.34 ± 5.72	
Attention Sx (CBCL) (11,483)	5.53 ± 4.32	4.23 ± 4.04	2.80 ± 3.36	2.86 ± 3.40	2.91 ± 3.44	
Thought Sx (CBCL) (11,483)	3.28 ± 3.42	2.24 ± 2.79	1.53 ± 2.08	1.56 ± 2.12	1.59 ± 2.17	
Social Sx (CBCL) (11,483)	3.36 ± 3.19	2.31 ± 2.68	1.53 ± 2.18	1.56 ± 2.21	1.59 ± 2.25	
Cognition Composite (11,249)	81.65 ± 8.62	84.62 ± 9.41	86.49 ± 9.09	86.42 ± 9.11	86.32 ± 9.12	
Sleep problems (SDSC) (11,363)	41.94 ± 13.52	38.88 ± 9.79	36.14 ± 8.13	36.24 ± 8.21	36.36 ± 8.39	
BMI (11,462)	20.72 ± 5.89	19.73 ± 4.31	18.76 ± 4.18	18.79 ± 4.19	18.84 ± 4.24	
Gestational age at birth: weeks (11,414)	39.31 ± 1.81	39.19 ± 2.06	39.07 ± 2.20	39.07 ± 2.20	39.08 ± 2.92	
Total Gray Matter Volume (11,407)	9.98 ± 0.90	10.22 ± 0.95	10.39 ± 1.00	10.38 ± 1.00	10.38 ± 1.00	
Total White Matter Volume (10,790)	8.71 ± 0.95	8.92 ± 1.07	9.04 ± 0.99	9.04 ± 1.00	9.03 ± 1.00	
Total Intracranial Volume(11,410)	9.89 ± 0.87	10.06 ± 0.94	10.16 ± 1.00	10.16 ± 1.00	10.15 ± 1.00	

383 **Table 1 Note.** Data included in analyses were required to have a response of yes or no for  
384 maternal report of using marijuana prior to and post knowledge of pregnancy. <sup>a</sup>Race/Ethnicity  
385 variables were coded as non-mutually exclusive dichotomous variables; as such, these numbers  
386 do not sum to 100% as participants could be included in multiple categories. <sup>b</sup>Family history of  
387 depression, psychosis, mania, antisocial behavior, and anxiety among 1<sup>st</sup> degree relatives.  
388 Psychotic-like experiences measured by the Prodromal Questionnaire-Brief Child Version total  
389 score. CBCL = Child Behavior Checklist. Cognition Composite assessed using the National  
390 Institute of Health Toolbox. BMI = Body Mass Index. Sleep problems from the Parent Sleep  
391 Disturbance Scale for Children

392  
393  
394  
395

**Table 2. Mixed Effects Regression Results for Prenatal Cannabis Exposure Among 10,404-11,489 Children Without Inclusion of Potentially Confounding Covariates.**

Outcome	MJ exposure post-knowledge			MJ exposure pre-knowledge			N
	B [95% CI]	p	pFDR	B [95% CI]	p	pFDR	
Psychotic-like Experiences	1.12 [.70, 1.5]	<b>2.21e-07</b>	<b>3.44e-07</b>	0.795 [.53, 1.1]	<b>3.65e-09</b>	<b>7.30e-09</b>	11477
Internalizing (CBCL)	2.42 [1.8, 3.1]	<b>7.00e-13</b>	<b>1.63e-12</b>	1.78 [1.4, 2.2]	<b>2.27e-17</b>	<b>5.30e-17</b>	11483
Externalizing (CBCL)	4.68 [4.0, 5.4]	<b>1.17e-42</b>	<b>1.64e-41</b>	2.93 [2.5, 3.3]	<b>3.93e-43</b>	<b>5.50e-42</b>	11483
Attention (CBCL)	2.37 [1.9, 2.8]	<b>8.89e-27</b>	<b>4.15e-26</b>	1.71 [1.4, 2.0]	<b>2.59e-35</b>	<b>1.81e-34</b>	11483
Thought (CBCL)	1.36 [1.1, 1.6]	<b>1.63e-25</b>	<b>5.71e-25</b>	0.870 [.71, 1.0]	<b>7.75e-27</b>	<b>2.71e-26</b>	11483
Social (CBCL)	1.54 [1.3, 1.8]	<b>3.59e-29</b>	<b>2.51e-28</b>	0.984 [.82, 1.2]	<b>8.87e-31</b>	<b>4.14e-30</b>	11483
Body Mass Index	1.31 [.80, 1.8]	<b>6.58e-07</b>	<b>9.21e-07</b>	0.945 [.62, 1.3]	<b>8.76e-09</b>	<b>1.53e-08</b>	11462
Cognition Composite	-3.83 [-5.0, -2.7]	<b>1.87e-10</b>	<b>3.74e-10</b>	-2.08 [-2.8, -1.4]	<b>2.22e-08</b>	<b>3.45e-08</b>	11249
Sleep Problems	4.04 [3.0, 5.0]	<b>1.89e-15</b>	<b>5.29e-15</b>	2.88 [2.3, 3.5]	<b>9.29e-20</b>	<b>2.60e-19</b>	11489
Gestational Age at Birth	0.142 [-.11, .40]	0.271	0.271	0.076 [-.08, .23]	0.334	0.334	11414
Birth Weight	-3.39 [-5.4, -1.3]	<b>0.00123</b>	<b>0.00132</b>	-1.75 [-3.0, -.49]	<b>0.00648</b>	<b>0.00698</b>	11113
Intracranial Volume	-0.273 [-.39, -.15]	<b>7.37e-06</b>	<b>9.38e-06</b>	0.157 [-.23, -.08]	<b>3.72e-05</b>	<b>4.34e-05</b>	11024
White Matter Volume	-0.298 [-.43, -.16]	<b>1.49e-05</b>	<b>1.74e-05</b>	-0.184 [-.27, -.10]	<b>1.92e-05</b>	<b>2.44e-05</b>	10404
Gray Matter Volume	-0.382 [-.51, -.25]	<b>7.77e-09</b>	<b>1.36e-08</b>	-0.230 [-.31, -.15]	<b>2.65e-08</b>	<b>3.71e-08</b>	11020


**Note.** Linear mixed effect models were used to analyze the associations between pre- and post-knowledge of pregnancy use of cannabis (analyzed separately) and each outcome, nesting data by research site and family ID (non-imaging analyses) and scanner and family ID (imaging analyses). Psychotic-like experiences were assessed with the Prodromal Questionnaire Brief-Report Child Version; CBCL = Child Behavior Checklist; uncorrected Cognition Composite from the NIH Toolbox; Sleep problems from the Parent Sleep Disturbance Scale for Children. N's differ due to listwise deletion of missing data. All Bs are unstandardized. Values in [] represent 95% Confidence Intervals. *pFDR* = p-values after false discovery rate correction for multiple testing, calculated separately for pre- and post-knowledge cannabis exposure. Bolded values indicate significant associations.

**Table 3. Associations Between Prenatal Cannabis Exposure When Including Potentially Confounding Covariates.**

Outcome	MJ exposure post-knowledge		MJ exposure pre-knowledge		N
	B [95% CI]	p	B [95% CI]	p	
Psychotic-like Experiences	0.941 [.25, 1.6]	<b>0.00810</b>	-0.091 [-.48, .30]	0.647	8165
Internalizing (CBCL)	1.15 [.08, 2.2]	<b>0.0359</b>	-0.053 [-.66, .55]	0.862	8168
Externalizing (CBCL)	1.90 [.84, 3.0]	<b>4.63e-04</b>	0.146 [-.45, .74]	0.630	8168
Attention (CBCL)	1.14 [.44, 1.8]	<b>0.00136</b>	0.205 [-.19, .60]	0.305	8168
Thought (CBCL)	0.523 [.11, .94]	<b>0.0134</b>	0.129 [-.10, .36]	0.277	8168
Social (CBCL)	0.942 [.51, 1.4]	<b>2.00e-05</b>	0.070 [-.17, .31]	0.572	8168
Body Mass Index	0.456 [-.36, 1.3]	0.275	-0.022 [-.48, .44]	0.925	8151
Cognition Composite	-1.69 [-3.3, -.04]	<b>0.0457</b>	0.887 [-.04, 1.8]	0.0609	8000
Total sleep problems	0.867 [-.76, 2.5]	0.296	0.370 [-.54, 1.3]	0.428	8169
Birth weight (oz)	-3.42 [-6.5, -.38]	<b>0.0278</b>	0.871 [-.84, 2.6]	0.318	8169
Intracranial Volume	0.010 [-.16, .18]	0.912	0.025 [-.07, .12]	0.614	7846
White matter	-0.030 [-.15, .09]	0.624	-0.037 [-.10, .03]	0.288	7431
Gray matter	-0.020 [-.12, .08]	0.711	0.037 [-.02, .10]	0.212	7842

**Note.** Fixed-effect covariates included: (1-4) prenatal exposure to alcohol or tobacco before or after knowledge of pregnancy; (5) household income; (6) maternal education level; (7) maternal age at birth; (8) whether the pregnancy was planned (0 = planned, 1 = unplanned); (9) length of time (weeks) pregnant before maternal knowledge of pregnancy; (10) prenatal vitamin use; (11-17) child race/ethnicity: Caucasian, African American, Asian, Native American, Pacific Islander, Hispanic, other; (18) birth weight (not included in model with birth weight as the outcome); (19) child sex (0 = male, 1 = female); (20) child age; (21-22) child substance use: alcohol sip, tobacco use; (23-27) first-degree familial history of mental illness: depression, psychosis, anxiety, mania, antisocial behavior; (28) whether the child has a twin or triplet in the study (0 = singleton or sibling, 1 = twin or triplet). Owing to the limited endorsement of ever having a marijuana puff among children (n = 14), we did not include this variable as a covariate. However, excluding these individuals does not meaningfully alter associations, nor does excluding children who used other substances, were prenatally exposed to other illicit substances, or children born at extreme prematurity (**Supplemental eTables 10-12**). Total intracranial volume was included as an additional covariate in the white and gray matter models; however, excluding this as a covariate did not alter associations between exposure and gray and white matter volumes (all |Bs| < 0.060, all ps > 0.56). N's differ due to listwise deletion. All Bs are unstandardized. Values in [] represent 95% Confidence Intervals. Bolded values indicate significant associations. Full regression results are provided in **Supplemental eTables 2-4**. Log transforming outcomes, including only covariates significantly associated with the outcomes, or excluding any parent/caregiver report other than the mother, in the full regression models did not meaningfully alter any observed associations (**Supplemental eTables 5-8**). CBCL Externalizing and Cognition Composite subfacets are reported in **Supplemental eTable 9**.

**Figure 1. Prenatal Cannabis Exposure Post Maternal Knowledge of Pregnancy is Associated with Increased Psychopathology Risk (A-F), Reduced Cognition (G), and Reduced Birth Weight (H).**



**Figure 1 Legend.** Raw data values are plotted. As scales differ y axes are not directly comparable across panels. CBCL = Child Behavior Checklist. Statistics are presented in **Tables 2-3** and **Supplemental eTables 2-3**. Log--transforming data reduces differences in variability across groups and results in similar conclusions (**Supplemental eTable 5**).

## REFERENCES

1. Hasin DS. US Epidemiology of Cannabis Use and Associated Problems. *Neuropsychopharmacology*. 2018;43(1):195-212.
2. Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States. *JAMA*. 2019;322(2):167-169.
3. Yao JL, He QZ, Liu M, et al. Effects of Delta(9)-tetrahydrocannabinol (THC) on human amniotic epithelial cell proliferation and migration. *Toxicology*. 2018;394:19-26.
4. Basavarajappa BS, Nixon RA, Arancio O. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. *Mini Rev Med Chem*. 2009;9(4):448-462.
5. Fride E, Gobshtis N, Dahan H, Weller A, Giuffrida A, Ben-Shabat S. The endocannabinoid system during development: emphasis on perinatal events and delayed effects. *Vitam Horm*. 2009;81:139-158.
6. Young-Wolff KC, Sarovar V, Tucker LY, et al. Self-reported Daily, Weekly, and Monthly Cannabis Use Among Women Before and During Pregnancy. *JAMA Netw Open*. 2019;2(7):e196471.
7. Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014. *JAMA*. 2017;317(2):207-209.
8. Agrawal A, Rogers CE, Lessov-Schlaggar CN, Carter EB, Lenze SN, Grucza RA. Alcohol, Cigarette, and Cannabis Use Between 2002 and 2016 in Pregnant Women From a Nationally Representative Sample. *JAMA Pediatr*. 2019;173(1):95-96.
9. Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. *Future Neurol*. 2011;6(4):459-480.
10. Scheyer AF, Melis M, Trezza V, Manzoni OJJ. Consequences of Perinatal Cannabis Exposure. *Trends Neurosci*. 2019.
11. Volkow ND, Compton WM, Wargo EM. The Risks of Marijuana Use During Pregnancy. *JAMA*. 2017;317(2):129-130.
12. Jansson LM, Jordan CJ, Velez ML. Perinatal Marijuana Use and the Developing Child. *JAMA*. 2018;320(6):545-546.
13. National Academies of Sciences E, Medicine. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press; 2017.
14. General OotS. U.S. Surgeon General's Advisory: Marijuana Use and the Developing Brain. 2019; <https://www.hhs.gov/surgeongeneral/reports-and-publications/addiction-and-substance-misuse/advisory-on-marijuana-use-and-developing-brain/index.html#>. Accessed 10/16/2019, 2019.
15. Ryan SA, Ammerman SD, O'Connor ME, Committee On Substance USE, Prevention, Section On B. Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes. *Pediatrics*. 2018;142(3).
16. Smith AM, Mioduszewski O, Hatchard T, Byron-Alhassan A, Fall C, Fried PA. Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. *Neurotoxicol Teratol*. 2016;58:53-59.
17. Leech SL, Richardson GA, Goldschmidt L, Day NL. Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. *Neurotoxicol Teratol*. 1999;21(2):109-118.



18. Corsi DJ, Walsh L, Weiss D, et al. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. *JAMA*. 2019;322(2):145-152.
19. Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. *Neurotoxicol Teratol*. 2005;27(3):439-448.
20. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol Teratol*. 2000;22(3):325-336.
21. Day NL, Goldschmidt L, Day R, Larkby C, Richardson GA. Prenatal marijuana exposure, age of marijuana initiation, and the development of psychotic symptoms in young adults. *Psychol Med*. 2015;45(8):1779-1787.
22. Dahl RE, Scher MS, Williamson DE, Robles N, Day N. A longitudinal study of prenatal marijuana use. Effects on sleep and arousal at age 3 years. *Arch Pediatr Adolesc Med*. 1995;149(2):145-150.
23. Zammit S, Thomas K, Thompson A, et al. Maternal tobacco, cannabis and alcohol use during pregnancy and risk of adolescent psychotic symptoms in offspring. *Br J Psychiatry*. 2009;195(4):294-300.
24. Ruisch IH, Dietrich A, Glennon JC, Buitelaar JK, Hoekstra PJ. Maternal substance use during pregnancy and offspring conduct problems: A meta-analysis. *Neurosci Biobehav Rev*. 2018;84:325-336.
25. Huizink AC. Prenatal cannabis exposure and infant outcomes: overview of studies. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;52:45-52.
26. Fine JD, Moreau AL, Karcher NR, et al. Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study. *JAMA Psychiatry*. 2019;76(7):762-764.
27. Buckley NE, Hansson S, Harta G, Mezey E. Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. *Neuroscience*. 1998;82(4):1131-1149.
28. Zurolo E, Iyer AM, Spliet WG, et al. CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. *Neuroscience*. 2010;170(1):28-41.
29. Volkow ND, Koob GF, Croyle RT, et al. The conception of the ABCD study: From substance use to a broad NIH collaboration. *Dev Cogn Neurosci*. 2018;32:4-7.
30. Karcher NR, Barch DM, Avenevoli S, et al. Assessment of the Prodromal Questionnaire-Brief Child Version for Measurement of Self-reported Psychoticlike Experiences in Childhood. *JAMA Psychiatry*. 2018;75(8):853-861.
31. Loewy RL, Pearson R, Vinogradov S, Bearden CE, Cannon TD. Psychosis risk screening with the Prodromal Questionnaire--brief version (PQ-B). *Schizophr Res*. 2011;129(1):42-46.
32. Achenbach TM. *Manual for the ASEBA school-age forms & profiles : an integrated system of multi-informant assessment* Burlington, VT, USA.: ASEBA; 2001.
33. Bruni O, Ottaviano S, Guidetti V, et al. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. *J Sleep Res*. 1996;5(4):251-261.
34. Akshoomoff N, Beaumont JL, Bauer PJ, et al. VIII. NIH Toolbox Cognition Battery (CB): composite scores of crystallized, fluid, and overall cognition. *Monogr Soc Res Child Dev*. 2013;78(4):119-132.

35. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *2015*. 2015;67(1):48.
36. Bogdan R, Baranger DAA, Agrawal A. Polygenic Risk Scores in Clinical Psychology: Bridging Genomic Risk to Individual Differences. *Annu Rev Clin Psychol*. 2018;14:119-157.
37. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427.
38. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet*. 2018;50(8):1112-1121.
39. Pasmán JA, Verweij KJH, Gerring Z, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. *Nat Neurosci*. 2018;21(9):1161-1170.
40. Warrington NM, Beaumont RN, Horikoshi M, et al. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. *Nat Genet*. 2019;51(5):804-814.
41. Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the U.S.: A review. *Prev Med*. 2017;104:13-23.
42. Dickson B, Mansfield C, Guiahi M, et al. Recommendations From Cannabis Dispensaries About First-Trimester Cannabis Use. *Obstet Gynecol*. 2018;131(6):1031-1038.
43. de Salas-Quiroga A, Diaz-Alonso J, Garcia-Rincon D, et al. Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. *Proc Natl Acad Sci U S A*. 2015;112(44):13693-13698.
44. Fugedi G, Molnar M, Rigo J, Jr., Schonleber J, Kovalszky I, Molvarec A. Increased placental expression of cannabinoid receptor 1 in preeclampsia: an observational study. *BMC Pregnancy Childbirth*. 2014;14:395.
45. Baranger DAA, Bogdan R. Editorial: Causal, Predispositional, or Correlate? Group Differences in Cognitive Control-Related Brain Function in Cannabis-Using Youth Raise New Questions. *J Am Acad Child Adolesc Psychiatry*. 2019;58(7):665-667.
46. Baranger DAA, Demers CH, Elsayed NM, et al. Convergent evidence for predispositional effects of brain gray matter volume on alcohol consumption. *Biological Psychiatry*.
47. Demontis D, Rajagopal VM, Thorgeirsson TE, et al. Genome-wide association study implicates CHRNA2 in cannabis use disorder. *Nat Neurosci*. 2019;22(7):1066-1074.
48. Murphy SK, Itchon-Ramos N, Visco Z, et al. Cannabinoid exposure and altered DNA methylation in rat and human sperm. *Epigenetics*. 2018;13(12):1208-1221.
49. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007;370(9584):319-328.
50. Mason O, Morgan CJ, Dhiman SK, et al. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. *Psychol Med*. 2009;39(6):951-956.
51. Power RA, Verweij KJ, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. *Mol Psychiatry*. 2014;19(11):1201-1204.
52. Carey CE, Agrawal A, Bucholz KK, et al. Associations between Polygenic Risk for Psychiatric Disorders and Substance Involvement. *Front Genet*. 2016;7:149.

53. Verweij KJ, Abdellaoui A, Nivard MG, et al. Short communication: Genetic association between schizophrenia and cannabis use. *Drug Alcohol Depend.* 2017;171:117-121.
54. Vaucher J, Keating BJ, Lasserre AM, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. *Mol Psychiatry.* 2018;23(5):1287-1292.
55. Gage SH, Jones HJ, Burgess S, et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. *Psychol Med.* 2017;47(5):971-980.
56. Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. *Br J Psychiatry.* 2011;198(3):173-175.
57. D'Onofrio BM, Van Hulle CA, Waldman ID, et al. Smoking during pregnancy and offspring externalizing problems: an exploration of genetic and environmental confounds. *Dev Psychopathol.* 2008;20(1):139-164.
58. Skoglund C, Chen Q, D'Onofrio BM, Lichtenstein P, Larsson H. Familial confounding of the association between maternal smoking during pregnancy and ADHD in offspring. *J Child Psychol Psychiatry.* 2014;55(1):61-68.
59. Palmer RH, Bidwell LC, Heath AC, Brick LA, Madden PA, Knopik VS. Effects of Maternal Smoking during Pregnancy on Offspring Externalizing Problems: Contextual Effects in a Sample of Female Twins. *Behav Genet.* 2016;46(3):403-415.
60. Knopik VS, Heath AC, Marceau K, et al. Missouri Mothers and Their Children: A Family Study of the Effects of Genetics and the Prenatal Environment. *Twin Res Hum Genet.* 2015;18(5):485-496.
61. Quinn PD, Rickert ME, Weibull CE, et al. Association Between Maternal Smoking During Pregnancy and Severe Mental Illness in Offspring. *JAMA Psychiatry.* 2017;74(6):589-596.
62. Knopik VS, Neiderhiser JM, de Geus E, Boomsma D. The Importance of the Prenatal Environment in Behavioral Genetics: Introduction to Special Issue. *Behav Genet.* 2016;46(3):281-285.
63. D'Onofrio BM, Class QA, Rickert ME, et al. Translational Epidemiologic Approaches to Understanding the Consequences of Early-Life Exposures. *Behav Genet.* 2016;46(3):315-328.
64. Seiler NK. Alcohol and Pregnancy: CDC's Health Advice and the Legal Rights of Pregnant Women. *Public Health Rep.* 2016;131(4):623-627.
65. Hopson MB, Margolis A, Rauh V, Herbstman J. Impact of the home environment on the relationship between prenatal exposure to environmental tobacco smoke and child behavior. *Int J Child Health Hum Dev.* 2016;9(4):453-464.
66. Bishai R, Koren G. Maternal and obstetric effects of prenatal drug exposure. *Clin Perinatol.* 1999;26(1):75-86, vii.
67. Garg M, Garrison L, Leeman L, et al. Validity of Self-Reported Drug Use Information Among Pregnant Women. *Matern Child Health J.* 2016;20(1):41-47.
68. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry.* 2019;6(5):427-436.
69. Frau R, Miczan V, Traccis F, et al. Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. *Nat Neurosci.* 2019.

70. Dong C, Chen J, Harrington A, Vinod KY, Hegde ML, Hegde VL. Cannabinoid exposure during pregnancy and its impact on immune function. *Cell Mol Life Sci.* 2019;76(4):729-743.